Appointment of Mr. Dhiren Shah, Mr. Sunil Shah as an Additional Directors and recommendation of Ms. Anjana Shah, Ashish Shah as an Independent Directors subject to prior approval of shareholders ....

Date: August 14, 2026 PPL/BSE/26-27/Q1 Department of Corporate Services, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code : 540359 Scrip ID : PARMAX Sub.: Outcome of Board Meeting held today i.e. Friday, August 14, 2026, pursuant to Regulation 30 and 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 Dear Sir/Ma’am, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors at its meeting held today i.e. Friday, August 14, 2026 has, inter-alia, considered and approved the following: 1). the Unaudited Financial Results for the Quarter ended June 30, 2026, a copy of the same is enclosed here (Annexure - A) along with the Limited Review Report issued by the Statutory Auditors in accordance with Regulation 33 of the Listing Regulations; 2). Appointment of Mr. Dhiren Chandulal Shah (DIN: 00255333) as an Additional Director – Non-Executive and Chairman of the Company with effect from August 14, 2026; 3). Appointment of Mr. Sunil Shah (DIN: 11888388) as an Additional Director - Non -Executive August 14, 2026; 4). Recommendation of Appointment of Mrs. Anjana Paresh Shah (DIN: 00845784) as Non-Executive Independent Director for 5 years in the ensuing annual general meeting (AGM) w.e.f. from the date of AGM ; 5) Recommendation of Appointment of Mr. Ashish Atmaram Shah (DIN: 06873593) as Non-Executive Independent Director for 5 years in the ensuing annual general meeting(AGM) w.e.f. from the date of AGM; 6) Resignation of Ms. Salma Thobhani (DIN: 11616267) as non-executive director w.e.f. from the closing of the business hour of 14th August, 2026. Pursuant to information as required pursuant to BSE circular no. LIST/COMP/14/2018-19 dated June 20, 2018, Mr. Dhiren Chandulal Shah, Mr. Sunil Shah, Mrs. Anjana Paresh Shah and Mr. Ashish Atmaram Shah have confirmed that they are not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority. The relevant details as per the requirement of Regulation 30 of SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed in ‘Annexure - The Board meeting commenced at 4.30 p.m. and concluded at 6.30 p.m. The above is for your kind information and record. You are requested to acknowledge the receipt. Thanking you, Yours faithfully, For Parmax Pharma Limited Umang Gosalia Managing Director DIN:05153830 Encl. as above Statement of Standalone Audited Results for the Quarter ended 30.06.2026 (In Rs. Thousands) Quarter Ended Preceding Quarter Corresponding Previous Year 30.06.2026 Ended 31.03.2026 Quarter Ended Ended 30.06.2025 31.03.2026 (Refer Notes Below) (Un Audited) (Audited) (Un Audited) (Audited) I. Revenue from operations 82209.52 33127.07 19423.11 121115.93 II. Other income 20791.30 258.75 66.85 468.06 III. Total Income (I+II) 103000.81 33385.81 19489.96 121583.99 IV. Expenses (a) Cost of materials consumed 50389.23 64079.68 8496.81 130633.91 (b) Purchase of stock-in-trade 0 0.00 .00 0 (c) Changes in inventories of finished goods, 6851.24 -31545.79 1226.39 -31800.34 work-in-progress and stock-in-trade (d) Employee benefits expense 6417.39 4220.20 6315.11 25049.355 (e) Finance Costs 2290.62 4962.66 2801.02 12399.56 (f) Depreciation and amortisation expense 4792.02 2498.00 2412.42 10135.0157 (g) Other expenses 10265.40 11880.87 33623.79 5883.19 Total expenses (IV) 81005.89 56095.61 27134.94 180041.29 Profit/(Loss) from operations before V 21994.93 -22709.80 -7644.98 -58457.30 exceptional items and tax (I-IV) VI Exceptional Items .00 0.00 0 0 VII Profit/ (Loss) before tax (V-VI) 21994.93 -22709.80 -7644.98 -58457.30 VIII Tax expense: (1) Current tax 0 0.00 0 0 (2) Deferred tax 0 -16866.49 0 -16866.486 Net Profit / (Loss) for the period from IX 21994.93 -5843.31 -7644.98 -41590.82 continuing operations (VII-VIII) X Profit/(loss) from discontinued operations XI Tax expense of discontined operations 0 0.00 0 0 Profit/(loss) from Discontined operations XII 0 0.00 0 0 (after tax) (X-XI) XIII Profit (Loss) for the period (IX+XII) 21994.93 -5843.31 -7644.98 -41590.82 Other Comprehensive Income A. (i) Items that will not be reclassifled to profit or loss (ii) Income tax relating to items that will not XIV be reclassified to profit or loss 0 0.00 0 B. (i) Items that will be reclassified to profit or loss (ii) lncome tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period XV (XIII+XIV) Comprising Profit (Loss) and 21994.93 -5843.31 -7644.98 -41590.82 Other comprehensive Income for the period) Paid-up equity share capital (Face Value Rs XVI 37413000 37413000.00 37413000 37413000 Earnings per share (for continuing operation XVII & discontinuing operation) (of Rs. 10/- each ): (a) Basic 5.88 -1.56 -2.04 -11.12 (b) Diluted 0.00 0.00 0.00 0.00 N otes: 1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th August, 2026 and The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter ended 30th June, 2026 2. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only. 3. Statement of Un-audited Financial Results of the company for the Quarter 30th June, 2026, in the prescribed format under Schedule III of Companies Act, 2013 4. The figures for the previous period have been re-grouped wherever necessary. 5. During the quarter ended 30.06.2026, Company has not charged the depreciation on the effluent treatment plant. 6. The Company has received Rs. 2.07 Crore from the Insurance Company towards settlement of the claim which has been recognised under other Income as an exceptional item. All assets remaining under insurance claim receivable has been capitalised FOR, PARMAX PHARMA LIMITED Place Hadamtala (Rajkot) Umang Alkesh Gosalia Date: 14.08.2026 Managing Director ANNEXURE-B APPOINTMENT OF MR. DHIREN CHANDULAL SHAH REASON FOR CHANGE VIZ. Appointment of Mr. Dhiren Chandulal Shah (DIN: 00255333) as Additional APPOINTMENT Director DATE OF APPOINTMENT 14th August, 2026 TERM OF APPOINTMENT Till the ensuing Annual General Meeting. He holds a Bachelor's degree in Science (B.Sc.) from Mithibai College. He has around 30+ years of extensive experience in business strategies, development, customer relationships, and strategic growth, with a strong focus on understanding market demand, unmet needs, demanding quality excellence, process innovation, and global presence in the pharma BRIEF PROFILE industry. Mr. Shah is one of the promoter director of Eastern Chemicals (Mumbai) Pvt Limited, (ECMPL) which enjoys a good credibility among overseas & domestic customers and suppliers in the pharmaceuticals industry. DISCLOSURE OF RELATIONSHIPS BETWEEN DIRECTORS (IN CASE OF Not Applicable APPOINTMENT OF A DIRECTOR). APPOINTMENT OF MR. SUNIL SHAH REASON FOR CHANGE VIZ. Appointment of Mr. Sunil Shah (DIN: 11888388) as Additional Director APPOINTMENT DATE OF APPOINTMENT 14th August, 2026 TERM OF APPOINTMENT Till the ensuing Annual General Meeting. He holds a Bachelor's degree in Chemical Engineering from D. D. Institute of Technology. He has around 30+ years of experience in the pharma BRIEF PROFILE industry. Mr. Shah is the proprietor of Risha Chemical and Sales that has built strong expertise in pharmaceutical trading, business development, customer relationship management, and market expansion. DISCLOSURE OF RELATIONSHIPS BETWEEN DIRECTORS (IN CASE OF Not Applicable APPOINTMENT OF A DIRECTOR). APPOINTMENT OF MRS. ANJANA PARESH SHAH REASON FOR CHANGE VIZ. Appointment of Mrs. Anjana Paresh Shah (DIN: 00845784) Non-Executive APPOINTMENT Independent Director DATE OF APPOINTMENT w.e.f. shareholder’s approva [Showing first 8,000 characters — download PDF for full document]